Xenocs and Malvern Panalytical collaborate to advance pharmaceutical analytics

We’re pleased to announce a collaboration between Small Angle X-ray Scattering specialists Xenocs and materials characterization experts Malvern Panalytical, both world leaders in their respective fields. 

Our joint marketing approach will enable us to provide a unique and comprehensive route to addressing analytical challenges in the pharmaceutical sector. Through various initiatives such as webinars and events, we’ll demonstrate how the instrumentation and expertise of both Xenocs and Malvern Panalytical can drive your understanding and elevate your operations.

Our collaboration will focus on pharmaceutical applications, with particular emphasis on nucleic acid drug products including mRNA-Vaccines, RNA therapeutics, and cell & gene therapies, as well as biologics such as peptides, where we observe an increasing need to understand structural features and how they impact a product’s stability and efficacy. 

"Xenocs and Malvern Panalytical provide complementary solutions to support the pharmaceutical industry in addressing its evolving challenges. We are excited about this collaboration and the benefits it will bring to our clients in this industry.”," states Frédéric Bossan, Xenocs’ Managing Director.

Martin Langley, Malvern Panalytical’s Sector Director - Pharmaceuticals and Food, adds: "This collaboration signifies a shared commitment to advancing the pharmaceutical industry and delivering enhanced value to our clients."

Our collaboration marks a significant step towards collectively shaping the future of analytical characterization in the pharmaceutical sector. We anticipate positive outcomes that will enhance the industry’s ability to address their ever-evolving analytical demands.

^{The agreement governing this project is intended solely for mutual cooperation and shall not be construed as creating a partnership, joint venture, or any other form of legal entity or business association between the parties.}